CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

The total solar eclipse will take place Monday, and parts of the local area are in the path of totality. Ohio has not seen a total eclipse since 1806 and will not see another one until 2099. The ...

Many were excited earlier this week to obtain the funky glasses needed for their families to watch the solar eclipse that covered much of America. Those who still have them around can help others feel ...

The National Thoroughbred Racing Association (NTRA), Daily Racing Form, and the National Turf Writers and Broadcasters (NTWAB) have announced that Frank Taylor and the Stable Recovery Program will be ...

COSHOCTON − Even though Coshocton County will be just outside the path of totality, many people locally will be looking to the sky on Monday to see the solar eclipse. The partial eclipse will begin in ...

MIDLAND, Texas — On Saturday, the Midland County Library will be hosting a Solar Eclipse Program event at 11 a.m. at the Downtown Library at the Plaza. 🌞🌑 Join us for an out-of-this-world experience ...

First patient enrolled in ECLIPSE 2 Phase 3 clinical trial evaluating the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis delta virus RNA despite ...